LeMaitre: A Vascular Surgery Pioneer Poised for Growth

LeMaitre Vascular, Inc. (Nasdaq: LMAT) has announced its participation in three upcoming investor conferences in March, providing an opportunity for investors to learn more about the company's innovative vascular surgery solutions and strong financial performance. As a provider of devices, implants, and services for the treatment of peripheral vascular disease, lemaitre has been a game-changer in the industry since 1983.



LeMaitre's commitment to innovation and customer satisfaction has driven its success in the market. The company's portfolio of product lines, including anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes, cater to the needs of vascular surgeons worldwide. Additionally, LeMaitre offers human vascular and cardiac tissue cryopreservation services, further expanding its offerings in the biologic space.

LeMaitre's financial performance has been consistently strong, with sales growth driven by key product lines such as grafts, carotid shunts, and catheters. In Q4 2024, sales increased by 14% (+14% organic) compared to Q4 2023, with APAC sales increasing by 21%, EMEA by 18%, and the Americas by 12%. The company's gross margin has also improved, reaching 69.3% in Q4 2024, a 121 basis point increase from Q4 2023. This improvement was due to higher ASPs and manufacturing efficiencies.



LeMaitre's operating income and margin have also been increasing, with operating income growing by 26% in Q4 2024 compared to Q4 2023. The company's operating margin was 23% in Q4 2024, with a full-year 2024 expectation of 25%. Earnings per share (EPS) have been growing consistently, with a 30% increase in Q4 2024 compared to Q4 2023 and a full-year 2024 expectation of 16% growth.



LeMaitre's strategic acquisitions, such as the acquisition of CryoLife, Inc. in 2019, have contributed to its organic growth and overall valuation. These acquisitions have allowed the company to expand its product portfolio and market reach, further solidifying its position as a leader in the peripheral vascular disease treatment segment.

In conclusion, lemaitre vascular, Inc. is a vascular surgery pioneer with a strong focus on innovation, customer satisfaction, and financial performance. The company's participation in upcoming investor conferences in March provides an opportunity for investors to learn more about its cutting-edge solutions and impressive financial track record. With a commitment to growth and a diverse product portfolio, LeMaitre is well-positioned to continue its success in the market.